Benzinga··Vandana SinghIDEAYA's Eye Cancer Drug Combo Demolishes Standard Therapy in Pivotal Trial
$IDYA's darovasertib-crizotinib combination doubled progression-free survival in metastatic uveal melanoma versus standard care, with FDA submission planned for late 2026.
IDYAFDA approvalprogression-free survival